Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Feb 3:4:PO.19.00272.
doi: 10.1200/PO.19.00272. eCollection 2020.

Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma

Marina Kushnirsky  1 , Lynn G Feun  2   3 , Sakir H Gultekin  4 , Macarena I de la Fuente  1   2
Affiliations
Case Reports

Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma

Marina Kushnirsky et al. JCO Precis Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Lynn G. FeunResearch Funding: Merck Sharp & Dohme (Inst)Macarena I. de la FuenteConsulting or Advisory Role: Agios, Puma Biotechnology, Foundation Medicine, FORMA Therapeutics No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Magnetic resonance imaging (MRI), axial postgadolinium T1-weighted imaging. (A) Baseline brain MRI images, before starting dabrafenib and trametinib (D+T), demonstrated progression of disease into the surgical cavity, as well as new lesions in the left insular region and midbrain. (B) Brain MRI images at 1 month after initiation of D+T, confirming > 50% decrease of all measurable enhancing lesions. (C) Brain MRI images at 7 months of D+T, demonstrating disappearance of all enhancing disease.
FIG 2.
FIG 2.
Histologic features at diagnosis. (A) Hematoxylin and eosin stain (40× magnification). (B) Hematoxylin and eosin stain (20× magnification).Tumor sample demonstrating an infiltrative cellular astrocytic neoplasm with fibrillary background, nuclear atypia, mitoses, and vascular proliferation; consistent with glioblastoma, WHO grade 4.
FIG 3.
FIG 3.
Histologic features at tumor recurrence (second resection). (A) Glial fibrillary acidic protein immunohistochemical stain (20× magnification). (B) Hematoxylin and eosin image (40× magnification). Second resection shows a similarly high cellular malignant astrocytoma with nuclear atypia, focal gemistocytic morphology, abundant fibrillary processes, vascular proliferation, and mitoses.
See this image and copyright information in PMC

References

    1. Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro-oncol. 2018;20:iv1–iv86. - PMC - PubMed
    1. Thomas AA, Brennan CW, DeAngelis LM, et al. Emerging therapies for glioblastoma. JAMA Neurol. 2014;71:1437–1444. - PubMed
    1. Brennan CW, Verhaak RGW, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–477. [Erratum: Cell 157:753, 2014] - PMC - PubMed
    1. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121:397–405. - PubMed
    1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. - PubMed

Publication types